Figure 6

Effects of silencing of survivin expression on bortezomib sensitivity in other cancer cell with mutant p53. Cell treatment condition is the same as in Figure 5. Cells were then collected for western blots to determine survivin expression and/or caspase-3 activation. A, MDA-MB-231 breast cancer cells are with mutant p53. B, PC-3 prostate cancer cells are with p53 null.